United States Patent 8,728,441: Fentanyl Buccal, Sublingual and Gingival Dosage Forms

U.S. Patent No. 8,728,441 covers a method of administering fentanyl across the oral mucosa using a solid dosage form containing a high level of a saliva-activated effervescent system and a pH-adjusting base. The claims target the delivery mechanism rather than a particular tablet shape, fentanyl dose, adhesive polymer, or commercial product.

The patent’s practical scope was directed primarily to effervescent fentanyl products such as Fentora and technically similar buccal or sublingual products. Its ordinary patent term appears to have ended in 2021 based on the underlying priority chain. The claims therefore present little current blocking risk as an enforceable U.S. patent, although they remain relevant to historical litigation, freedom-to-operate analysis, and the design of follow-on products.

What does U.S. Patent 8,728,441 cover?

Claim 1 requires every element below:

Required element	Scope
Active ingredient	Fentanyl or a pharmaceutically acceptable salt
Route	Across oral mucosa
Dosage form	Solid oral dosage form
Therapeutic purpose	Analgesia
Administration sites	Buccal, sublingual, or gingival
Effervescent system	An acid plus a carbonate or bicarbonate base
Effervescent concentration	About 5% to about 80% by weight
pH adjustment	A listed carbonate, bicarbonate-related phosphate, or phosphate base
Administration	The dosage form must be administered to a mammal

The claim is a method claim. A product alone does not literally infringe claim 1 unless the product is made, sold, or used in a way that satisfies the claimed administration method. Claims 2 through 8 narrow the method by specifying the route, patient, dosage form, pH target, and pH level.

How broad is claim 1 of patent 8,728,441?

Claim 1 is broad in product composition but narrower in its combination of delivery requirements.

It does not require:

A particular fentanyl dose;
Fentanyl citrate specifically;
A particular tablet weight;
A mucoadhesive polymer;
A specific disintegration time;
A specific absorption percentage;
A branded product;
A particular commercial indication such as breakthrough cancer pain;
A specific acid-base ratio;
A defined particle size or manufacturing process.

The claim does require a saliva-activated effervescent couple. An acid and base must be present in the dosage form in an amount sufficient to increase fentanyl absorption through the oral mucosa. The effervescent couple must account for approximately 5% to 80% of the dosage form by weight.

The Markush lists are material. The acid must be selected from:

Citric acid;
Tartaric acid;
Malic acid;
Fumaric acid;
Adipic acid; or
Succinic acid.

The base must be selected from:

Sodium bicarbonate;
Sodium carbonate;
Potassium bicarbonate;
Potassium carbonate; or
Magnesium carbonate.

A formulation using a different acid or a different gas-generating base may avoid literal infringement, subject to the doctrine of equivalents and the patent’s prosecution history.

What do dependent claims 2 through 8 add?

Claim	Limitation
2	Buccal administration
3	Sublingual administration
4	Gingival administration
5	Human patient
6	Tablet dosage form
7	pH-adjusting substance selected to provide substantially neutral pH at the absorption site
8	The substantially neutral pH is slightly above 7

Claims 2, 3, and 4 are alternative route claims. A product administered to the cheek, under the tongue, or against gingival tissue may fall within a corresponding dependent claim if the claim 1 requirements are also met.

Claim 5 is commercially important because it narrows the mammal limitation to humans, which is the relevant population for approved fentanyl products.

Claim 6 limits the dosage form to a tablet. Claim 1, by contrast, can cover other solid oral forms, including certain lozenges, compressed units, or multiparticulate systems if they satisfy the remaining elements.

Claims 7 and 8 create pH-based fallback positions. The claim language does not establish a precise numerical pH range. “Substantially neutral” and “slightly higher than 7” would be interpreted using the specification, technical evidence, and prosecution history.

What formulations are protected by patent 8,728,441?

A formulation is closest to the claim scope when it contains fentanyl, a listed acid, a listed carbonate or bicarbonate base, and a listed pH-adjusting base.

Formulations likely within the literal scope

Examples include a fentanyl citrate tablet containing:

Citric acid and sodium bicarbonate as the effervescent pair;
Sodium carbonate or potassium carbonate as the pH-adjusting substance;
A combined effervescent system representing 5% to 80% of tablet weight;
Administration through the buccal, sublingual, or gingival mucosa.

A formulation may also satisfy the pH limitation where carbonate or phosphate salts raise the local mucosal environment to a substantially neutral or slightly alkaline pH.

Formulations that may fall outside the literal scope

Potential design-around categories include:

A non-effervescent fentanyl tablet;
A tablet using an acid outside the six listed acids;
A gas-generating base outside the five listed bases;
A dosage form in which the effervescent couple is below approximately 5% by weight;
A formulation administered intranasally, transdermally, intravenously, or orally for gastrointestinal absorption;
A formulation using a pH modifier outside the listed carbonate and phosphate compounds.

The 5% threshold is subject to ordinary claim construction. “About 5%” may cover a range around 5%, depending on the specification and technical evidence. The upper “about 80%” boundary raises the same issue.

How does patent 8,728,441 relate to Fentora?

Fentora is a fentanyl buccal tablet developed using CIMA Laboratories’ OraVescent technology and commercialized by Cephalon, later acquired by Teva Pharmaceutical Industries. The product uses an effervescent system intended to promote fentanyl release and transmucosal absorption. The Fentora label identifies fentanyl citrate as the active pharmaceutical ingredient and describes buccal administration for breakthrough pain in opioid-tolerant adults. [2]

The technical overlap is substantial:

Characteristic	U.S. 8,728,441 claim scope	Fentora
Active ingredient	Fentanyl or salt	Fentanyl citrate
Dosage form	Solid oral dosage form	Buccal tablet
Route	Buccal, sublingual, or gingival	Buccal
Effervescence	Required	Core OraVescent feature
pH adjustment	Required	Consistent with formulation technology
Patient	Mammal, with human dependent claim	Human patients
Indication	Analgesia	Breakthrough cancer pain in opioid-tolerant patients

The claim is not limited to Fentora. It can cover competing fentanyl products if their formulation and administration method satisfy every limitation.

When did patent 8,728,441 expire?

The patent issued on May 20, 2014. Its term is tied to an earlier patent family associated with the CIMA effervescent oral transmucosal technology. On the ordinary 20-year term calculation, the relevant expiration was in 2021, before considering any patent-term adjustment or patent-term extension.

The patent is therefore not a current long-term exclusivity barrier in the United States. Any analysis of present generic entry must focus on:

Other unexpired patents;
FDA regulatory exclusivity;
Product-specific labeling restrictions;
Patent settlements;
Trade-secret manufacturing processes;
Abuse-deterrent or device-related rights;
State and federal controlled-substance requirements.

Patent expiry does not itself authorize a product launch. A sponsor still requires an approved FDA application and must satisfy fentanyl-specific safety, labeling, distribution, and controlled-substance requirements.

What was the Orange Book status of patent 8,728,441?

The relevant Orange Book question is whether U.S. Patent No. 8,728,441 was listed against a specific approved fentanyl product, not whether the patent broadly related to fentanyl.

Orange Book listing is product-specific. A patent may be technically relevant to a dosage form but have no Orange Book effect unless the approved-product sponsor submitted it for listing and FDA accepted the listing. Method-of-use patents generally must contain a method corresponding to an approved use or be listed in the manner permitted by FDA regulations. [3]

The principal branded product associated with this technology was Fentora. The historically important patent estate for Fentora included multiple CIMA and Cephalon patents covering the buccal tablet, effervescent system, formulation, and methods of use. A complete Orange Book determination must distinguish patent 8,728,441 from related patents that may have carried different expiration dates or different listing status.

Because 8,728,441 has expired under the ordinary term calculation, it does not currently create a live Orange Book patent bar.

Which companies challenged Fentora exclusivity?

Fentora faced generic competition from companies seeking approval for fentanyl buccal tablets. The relevant challengers included generic manufacturers that filed abbreviated new drug applications and, in some cases, Paragraph IV certifications against listed patents.

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. Under the Hatch-Waxman statute, the filing of a Paragraph IV notice can trigger patent litigation and a potential 30-month stay of approval. [4]

The commercial relevance of a challenge depended on the full listed patent set. A generic applicant could avoid one patent yet remain blocked by another formulation or method patent. The expiry of the final enforceable patent, rather than the expiry of 8,728,441 alone, determined practical generic timing.

What patent litigation affected fentanyl buccal tablets?

Fentanyl buccal tablet litigation generally involved four categories:

Effervescent delivery technology;
Tablet composition and excipient ratios;
Buccal or transmucosal methods of use;
Product-specific labeling and approved indications.

The strongest litigation positions typically depended on formulation evidence. A patentee would need to show that the accused product used the claimed acid-base combination, contained the effervescent system at the claimed concentration, and was administered in the claimed manner.

For a method claim, evidence could include:

The generic product label;
Instructions for administration;
Product composition data;
ANDA records;
Manufacturing specifications obtained through discovery;
Expert analysis of local pH and oral mucosal absorption.

A generic manufacturer could reduce risk through a formulation design-around, a section viii label carve-out where legally available, or a litigation challenge to validity and claim construction.

How strong is the patent estate represented by patent 8,728,441?

The patent had meaningful historical strength against products using the same core technology, but its current exclusionary strength is low because the patent term has ended.

Historical strengths

It covered the method of administering fentanyl, not merely a composition.
It captured three oral-mucosal routes.
It used a broad 5% to 80% effervescent concentration range.
It included multiple common pharmaceutical acids and carbonate bases.
It linked effervescence to increased oral-mucosal absorption.
Dependent claims supplied human-use and tablet positions.

Structural weaknesses

The claim required a specific effervescent mechanism.
The acid and base lists were closed Markush groups.
The pH-adjustment requirement added another formulation limitation.
The claim did not cover non-effervescent fentanyl products.
The method required oral-mucosal administration.
The efficacy relationship between effervescence and increased absorption could create evidentiary disputes.
“About,” “substantially neutral,” and “slightly higher than 7” introduce claim-construction issues.

The patent was strongest against an OraVescent-style fentanyl tablet and weaker against non-effervescent, alternative-route, or materially different transmucosal products.

What generic launch scenarios existed for fentanyl buccal tablets?

Scenario 1: Same core formulation

A generic using fentanyl citrate, citric acid, sodium bicarbonate, carbonate pH adjustment, and buccal administration would have faced the highest historical infringement risk. Such a product would likely require a Paragraph IV strategy or a launch after patent expiry and settlement restrictions.

Scenario 2: Formulation design-around

A sponsor could use a different acid-base system, omit effervescence, or reduce the effervescent component below the claimed range. This would shift the dispute toward equivalents, specification support, and whether the alternative still produced substantially the same function in substantially the same way.

Scenario 3: Different delivery route

A sublingual product could still fall within claim 3. Nasal, transdermal, injectable, or gastrointestinal products would not satisfy the claimed oral-mucosal route.

Scenario 4: Label carve-out

A generic applicant could seek a limited label excluding a patented method of use. This strategy would depend on the approved indications, the exact listed method claims, FDA labeling rules, and whether the remaining label still encouraged the patented administration method.

How does patent 8,728,441 compare with other fentanyl products?

Product	Delivery route	Effervescent oral-mucosal technology	Main patent-risk profile
Fentora	Buccal tablet	Yes	Direct historical overlap
Actiq	Oral transmucosal lozenge on handle	No comparable tablet requirement	Different dosage-form and delivery structure
Abstral	Sublingual tablet	Product-specific formulation	Possible route overlap, but not necessarily effervescent overlap
Subsys	Sublingual spray	No solid oral dosage form	Outside the solid-tablet limitation
Lazanda	Intranasal spray	No oral mucosal delivery	Outside claim 1 route and dosage-form requirements
Transdermal fentanyl	Skin delivery	No	Outside oral-mucosal limitations

The patent was most relevant to Fentora-type tablets and less relevant to sprays, patches, and non-effervescent oral transmucosal products.

Does patent 8,728,441 create biosimilar risk?

No. Fentanyl is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway is an abbreviated new drug application for a generic drug, not a biosimilar application under the Public Health Service Act.

The main regulatory issues are bioequivalence, dosage-form performance, abuse potential, opioid-tolerant-patient labeling, and controlled-substance compliance. FDA’s product-specific guidance and ANDA requirements are more important than biosimilar interchangeability rules. [1, 5]

Key Takeaways

U.S. Patent 8,728,441 claims a method of administering fentanyl across the buccal, sublingual, or gingival mucosa.
The core technical requirement is a solid dosage form containing a listed acid-base effervescent couple at about 5% to 80% by weight.
A listed carbonate or phosphate base must also function as a pH-adjusting substance.
The claims are broad enough to cover multiple fentanyl salts and oral-mucosal dosage forms, but they are limited to specified chemical categories and effervescent delivery.
Fentora is the product with the clearest technical relationship to the claimed invention.
The patent’s ordinary term ended in 2021, eliminating it as a current U.S. patent barrier.
Historical generic risk depended on the full Fentora patent estate, not this patent alone.
Non-effervescent, non-oral, nasal, injectable, and transdermal fentanyl products are generally outside the literal scope.
Fentanyl competition is governed by generic-drug rules, not biosimilar rules.
Current launch analysis should focus on any surviving related patents, FDA exclusivity, approved labeling, and controlled-substance requirements.

FAQs about U.S. Patent 8,728,441

What fentanyl salts can fall within patent 8,728,441?

The claim covers fentanyl and any pharmaceutically acceptable salt. Fentanyl citrate is the principal commercial example associated with Fentora, but the claim is not limited to that salt.

Does a fentanyl lozenge infringe patent 8,728,441?

It could, but only if it is a solid oral dosage form containing the required effervescent and pH-adjusting substances and is administered across the oral mucosa. The claim is not limited to tablets.

Does a sublingual fentanyl product fall within the patent?

Potentially. Claim 3 expressly covers sublingual administration, but the product must also satisfy every limitation of claim 1.

Can a company avoid the patent by replacing sodium bicarbonate?

Potentially, if the replacement is outside the listed base group and is not equivalent to a claimed base. The full formulation and prosecution history would control the analysis.

Is patent 8,728,441 still relevant to FDA approval?

It is relevant as historical patent information and may remain relevant to patent-family analysis. Because its ordinary patent term ended in 2021, it should not independently prevent approval of a current generic product.

References

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (n.d.). Fentora (fentanyl buccal tablet) prescribing information.
U.S. Food and Drug Administration. (2023). 21 C.F.R. § 314.53: Submission of patent information.
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).
U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development.
U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,728,441, Methods of administering fentanyl.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	350017	⤷ Start Trial
Austria	433745	⤷ Start Trial
Austria	434432	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,728,441

Summary for Patent: 8,728,441